Effect of Oxidized Plant Sterols on Serum Concentrations of Plant Sterol Oxidation Products (POP)
- Conditions
- Healthy
- Interventions
- Other: cookies enriched with POP
- Registration Number
- NCT03312816
- Lead Sponsor
- Unilever R&D
- Brief Summary
The study is a randomised, double-blind, placebocontrolled, parallel dose-response study with four study arms. Sixty subjects will be randomly allocated to consume study products containing varying amounts of plant sterol (PS) oxidation products (POP) or placebo for 6 weeks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
- Apparently healthy men and women as judged by study physician.
- BMI > 18 and < 35 kg/m2.
- Total cholesterol levels at screening ≥5.0 and ≤8.0 mmol/L
- Blood pressure, heart rate, haematological and clinical chemical parameters within the normal reference range as judged by the study physician.
- Recently (<6 months) diagnosed with cardiovascular event(s) (stroke, TIA (Transient ischemic attack), angina, myocardial infarction, heart failure), revascularization or systemic inflammatory conditions.
- Use of plant-sterol/stanol-enriched foods or supplements in the three months prior to the screening and/or during the study.
- Use of over-the-counter and prescribed medication which may interfere with study measurements (i.e. statins, ezetimibe, fibrates, diabetic drugs, angiotensin receptor blockers (ARB) and ACE (Angiotensin-converting enzyme) inhibitors)), to be judged by the principal investigator.
- Use of oral antibiotics (with the exception of topical antibiotics) in 40 days or less prior to Day -2.
- Pregnant or lactating women.
- Reported alcohol consumption > 14 units/week (female) or > 21 units/week (male).
- Reported intense sporting activities > 10 hours/week.
- Reported weight loss or gain of 3 kg or more during a period of 6 months prior to screening.
- Currently on a medically- or self-prescribed diet, or slimming diet, or the intention to use any kind of diet during the study.
- Currently smoking or being a non-smoker for less than 6 months and reported use of any nicotine containing products in the 6 months prior to screening and/or during the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description low dosage cookies enriched with POP low added POP Medium dose cookies enriched with POP medium added POP Placebo cookies enriched with POP 0 mg/d added POP Hige dose cookies enriched with POP high added POP
- Primary Outcome Measures
Name Time Method POP (plant sterol oxidation products) value 0 to 42 days To estimate the change from baseline in serum POP concentration after intake of various POP doses.
- Secondary Outcome Measures
Name Time Method Ratio of serum POP concentration 0 to 42 days To estimate the ratio of serum POP concentrations vs. COP concentrations after intake of various POP doses.
COP (cholesterol oxidation products) value 0 to 42 days To estimate the change from baseline in serum COP concentrations after intake of various POP doses.
Trial Locations
- Locations (1)
Charité Research Organisation GmbH
🇩🇪Berlin, Germany